Schizophrenia as a GSK-3 dysregulation disorder

Trends in Neurosciences

Volumn 30, Issue 4, 2007, Pages 142-149

  Lovestone, Simon ^a   Killick, Richard ^a   Di Forti, Marta ^a   Murray, Robin ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; DOPAMINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; GLYCOGEN SYNTHASE KINASE 3; INSULIN; LITHIUM; VALPROIC ACID; WNT PROTEIN;

ARTICLE; BIPOLAR DISORDER; BRAIN DYSFUNCTION; COGNITIVE DEFECT; DISEASE PREDISPOSITION; DOPAMINE BRAIN LEVEL; ENZYME ACTIVITY; ENZYME REGULATION; GENETIC ASSOCIATION; HUMAN; NERVE CELL DIFFERENTIATION; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PSYCHOSIS; REGULATORY MECHANISM; SCHIZOPHRENIA;

ANIMALS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MODELS, BIOLOGICAL; SCHIZOPHRENIA; SIGNAL TRANSDUCTION;

EID: 33947587839     PISSN: 01662236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tins.2007.02.002     Document Type: Article

References (70)

1. Seeman P., et al. Psychosis pathways converge via D2(high) dopamine receptors. Synapse 60 (2006) 319-346
2. Bibb J.A. Decoding dopamine signaling. Cell 122 (2005) 153-155
3. Beaulieu J.M., et al. An Akt/β-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 122 (2005) 261-273
4. Ni C.Y., et al. γ-Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science 294 (2001) 2179-2181
5. Bao J., et al. Back signaling by the Nrg-1 intracellular domain. J. Cell Biol. 161 (2003) 1133-1141
6. Owen M.J., et al. Schizophrenia: genes at last?. Trends Genet. 21 (2005) 518-525
7. Straub R.E., and Weinberger D.R. Schizophrenia genes - famine to feast. Biol. Psychiatry 60 (2006) 81-83
8. Ross C.A., et al. Neurobiology of schizophrenia. Neuron 52 (2006) 139-153
9. Glatt S.J., et al. Five NOTCH4 polymorphisms show weak evidence for association with schizophrenia: evidence from meta-analyses. Schizophr. Res. 73 (2005) 281-290
10. Katsu T., et al. The human frizzled-3 (FZD3) gene on chromosome 8p21, a receptor gene for Wnt ligands, is associated with the susceptibility to schizophrenia. Neurosci. Lett. 353 (2003) 53-56
11. Yang J., et al. Association study of the human FZD3 locus with schizophrenia. Biol. Psychiatry 54 (2003) 1298-1301
12. Zhang Y., et al. Positive association of the human frizzled 3 (FZD3) gene haplotype with schizophrenia in Chinese Han population. Am. J. Med. Genet. B. Neuropsychiatr Genet. 129B (2004) 16-19
13. Wei J., and Hemmings G.P. Lack of a genetic association between the frizzled-3 gene and schizophrenia in a British population. Neurosci. Lett. 366 (2004) 336-338
14. Ide M., et al. Genetic and expression analyses of FZD3 in schizophrenia. Biol. Psychiatry 56 (2004) 462-465
15. Jeong S.H., et al. Investigation of genetic association between human Frizzled homolog 3 gene (FZD3) and schizophrenia: results in a Korean population and evidence from meta-analysis. Psychiatry Res. 143 (2006) 1-11
16. Fedi P., et al. Isolation and biochemical characterization of the human Dkk-1 homologue, a novel inhibitor of mammalian Wnt signaling. J. Biol. Chem. 274 (1999) 19465-19472
17. Adam L., et al. Tiam1 overexpression potentiates heregulin-induced lymphoid enhancer factor-1/β-catenin nuclear signaling in breast cancer cells by modulating the intercellular stability. J. Biol. Chem. 276 (2001) 28443-28450
18. Grant S., et al. Roles of ERBB family receptor tyrosine kinases, and downstream signaling pathways, in the control of cell growth and survival. Front. Biosci. 7 (2002) d376-d389
19. Thaminy S., et al. Identification of novel ErbB3-interacting factors using the split-ubiquitin membrane yeast two-hybrid system. Genome Res. 13 (2003) 1744-1753
20. Wu C., et al. RGS proteins inhibit Xwnt-8 signaling in Xenopus embryonic development. Development 127 (2000) 2773-2784
21. Hing H.K., et al. Modulation of wingless signaling by Notch in Drosophila. Mech. Dev. 47 (1994) 261-268
22. Camargo L.M., et al. Disrupted in Schizophrenia 1 Interactome: evidence for the close connectivity of risk genes and a potential synaptic basis for schizophrenia. Mol. Psychiatry 12 (2006) 74-86
23. Erbel-Sieler C., et al. Behavioral and regulatory abnormalities in mice deficient in the NPAS1 and NPAS3 transcription factors. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 13648-13653
24. Ohkubo N., et al. Apolipoprotein E and Reelin ligands modulate tau phosphorylation through an apolipoprotein E receptor/disabled-1/glycogen synthase kinase-3β cascade. FASEB J. 17 (2003) 295-297
25. Yang S.D., et al. Dysfunction of protein kinase FA/GSK-3α in lymphocytes of patients with schizophrenic disorder. J. Cell. Biochem. 59 (1995) 108-116
26. Emamian E.S., et al. Convergent evidence for impaired AKT1-GSK3β signaling in schizophrenia. Nat. Genet. 36 (2004) 131-137
27. Nadri C., et al. GSK-3 parameters in lymphocytes of schizophrenic patients. Psychiatry Res. 112 (2002) 51-57
28. Cotter D., et al. Abnormalities of Wnt signalling in schizophrenia - evidence for neurodevelopmental abnormality. Neuroreport 9 (1998) 1379-1383
29. Beasley C.L., et al. Glycogen synthase kinase-3β immunoreactivity is reduced in the prefrontal cortex in schizophrenia. Neurosci. Lett. 302 (2001) 117-120
30. Kozlovsky N., et al. Low GSK-3β immunoreactivity in postmortem frontal cortex of schizophrenic patients. Am. J. Psychiatry 157 (2000) 831-833
31. Kozlovsky N., et al. GSK-3β in cerebrospinal fluid of schizophrenia patients. J. Neural Transm. 111 (2004) 1093-1098
32. Beasley C., et al. An investigation of the Wnt-signalling pathway in the prefrontal cortex in schizophrenia, bipolar disorder and major depressive disorder. Schizophr. Res. 58 (2002) 63-67
33. Ide M., et al. Failure to support a genetic contribution of AKT1 polymorphisms and altered AKT signaling in schizophrenia. J. Neurochem. 99 (2006) 277-287
34. Kang U.G., et al. The effects of clozapine on the GSK-3-mediated signaling pathway. FEBS Lett. 560 (2004) 115-119
35. Li X., et al. Regulation of mouse brain glycogen synthase kinase-3 by atypical antipsychotics. Int. J. Neuropsychopharmacol. 10 (2006) 7-19
36. Kozlovsky N., et al. Psychotropic drugs affect Ser9-phosphorylated GSK-3 β protein levels in rodent frontal cortex. Int. J. Neuropsychopharmacol. 9 (2006) 337-342
37. Alimohamad H., et al. The effects of antipsychotics on beta-catenin, glycogen synthase kinase-3 and dishevelled in the ventral midbrain of rats. J. Neurochem. 95 (2005) 513-525
38. Svenningsson P., et al. Diverse psychotomimetics act through a common signaling pathway. Science 302 (2003) 1412-1415
39. Beaulieu J.M., et al. Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc. Natl. Acad. Sci. U. S. A 101 (2004) 5099-5104
40. Chen G., et al. The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J. Neurochem. 72 (1999) 1327-1330
41. Harwood A.J. Neurodevelopment and mood stabilizers. Curr. Mol. Med. 3 (2003) 472-482
42. Leucht S., et al. Lithium for schizophrenia revisited: a systematic review and meta-analysis of randomized controlled trials. J. Clin. Psychiatry 65 (2004) 177-186
43. Crawley J.N., and Paylor R. A proposed test battery and constellations of specific behavioral paradigms to investigate the behavioral phenotypes of transgenic and knockout mice. Horm. Behav. 31 (1997) 197-211
44. Lijam N., et al. Social interaction and sensorimotor gating abnormalities in mice lacking Dvl1. Cell 90 (1997) 895-905
45. Long J.M., et al. Expanded characterization of the social interaction abnormalities in mice lacking Dvl1. Genes Brain Behav. 3 (2004) 51-62
46. Amar S., et al. Genetic correlational analysis of glycogen synthase kinase-3β and prepulse inhibition in inbred mice. Genes Brain Behav. 3 (2004) 178-180
47. Bushe C., and Holt R. Prevalence of diabetes and impaired glucose tolerance in patients with schizophrenia. Br. J. Psychiatry Suppl. 47 (2004) S67-S71
48. Kohen D. Diabetes mellitus and schizophrenia: historical perspective. Br. J. Psychiatry Suppl. 47 (2004) S64-S66
49. Cannon T.D., et al. Fetal hypoxia and structural brain abnormalities in schizophrenic patients, their siblings, and controls. Arch. Gen. Psychiatry 59 (2002) 35-41
50. Haddad P.M. Antipsychotics and diabetes: review of non-prospective data. Br. J. Psychiatry Suppl. 47 (2004) S80-S86
51. Thakore J.H. Metabolic disturbance in first-episode schizophrenia. Br. J. Psychiatry Suppl. 47 (2004) S76-S79
52. Holmes E., et al. Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia. PLoS Med. 3 (2006) e327
53. Jope R.S., and Johnson G.V. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem. Sci. 29 (2004) 95-102
54. Kaytor M.D., and Orr H.T. The GSK3 β signaling cascade and neurodegenerative disease. Curr. Opin. Neurobiol. 12 (2002) 275-278
55. Hye A., et al. Glycogen synthase kinase-3 is increased in white cells early in Alzheimer's disease. Neurosci. Lett. 373 (2005) 1-4
56. Niizato K., et al. Cognitive decline in schizophrenics with Alzheimer's disease: a mini-review of neuropsychological and neuropathological studies. Prog. Neuropsychopharmacol. Biol. Psychiatry 25 (2001) 1359-1366
57. Harrison P.J. The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain 122 (1999) 593-624
58. Marenco S., and Weinberger D.R. The neurodevelopmental hypothesis of schizophrenia: following a trail of evidence from cradle to grave. Dev. Psychopathol. 12 (2000) 501-527
59. Wodarz A., and Nusse R. Mechanisms of Wnt signaling in development. Annu. Rev. Cell Dev. Biol. 14 (1998) 59-88
60. Anlar B., et al. Insulin-like growth factor-I and central nervous system development. Horm. Metab. Res. 31 (1999) 120-125
61. Castelo-Branco G., and Arenas E. Function of Wnts in dopaminergic neuron development. Neurodegener. Dis. 3 (2006) 5-11
62. Wang Y., et al. Frizzled-3 is required for the development of major fiber tracts in the rostral CNS. J. Neurosci. 22 (2002) 8563-8573
63. Diwadkar V.A., et al. Abnormalities in MRI-measured signal intensity in the corpus callosum in schizophrenia. Schizophr. Res. 67 (2004) 277-282
64. Ananth H., et al. Cortical and subcortical gray matter abnormalities in schizophrenia determined through structural magnetic resonance imaging with optimized volumetric voxel-based morphometry. Am. J. Psychiatry 159 (2002) 1497-1505
65. Salinas P.C. Synaptogenesis: Wnt and TGF-β take centre stage. Curr. Biol. 13 (2003) R60-R62
66. Franco B., et al. Shaggy, the homolog of glycogen synthase kinase 3, controls neuromuscular junction growth in Drosophila. J. Neurosci. 24 (2004) 6573-6577
67. Hooper C., et al. Glycogen synthase kinase-3 inhibition is integral to long-term potentiation. Eur. J. Neurosci. 25 (2007) 81-86
68. Ciani L., et al. A divergent canonical WNT-signaling pathway regulates microtubule dynamics: Dishevelled signals locally to stabilize microtubules. J. Cell Biol. 164 (2004) 243-253
69. Lovestone S., et al. Phosphorylation of tau by glycogen synthase kinase-3β in intact mammalian cells: the effects on organisation and stability of microtubules. Neuroscience 73 (1996) 1145-1157
70. Mudher A., et al. GSK-3β inhibition reverses axonal transport defects and behavioural phenotypes in Drosophila. Mol. Psychiatry 9 (2004) 522-530